Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M

CORCEPT THERAPEUTICS INC

2021-Q2 EPS reported $0.39 revenue$171,025,000

Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.
Cash and investments $471.6M, +$16.8M from Q1; repurchased 1.4M shares for $30.8M.
2021 revenue guidance reaffirmed at $355-385M; CEO cites easing COVID restrictions driving growth.
Phase 3 pivotal trial of relacorilant in platinum-resistant ovarian cancer expected to start Q1 2022.
GRACE Phase 3 trial for relacorilant in Cushing's syndrome continues; NDA submission planned Q2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.